biostudies-literatureUnknown15(4)Urso LLutathera^® is the first EMA- and FDA-approved radiopharmaceutical for radioligand therapy (RLT). Currently, on the legacy of the NETTER1 trial, only adult patients with progressive unresectable somatostatin receptor (SSTR) positive gastroenteropancreatic (GEP) neuroendocrine neoplasms (NET) can be treated with Lutathera^®. Conversely, patients with SSTR-positive disease arising from outside the gastroenteric region do not currently have access to Lutathera^® treatment despite several papers in the literature reporting the effectiveness and safety of RLT in these settings. Moreover, patients with well-differentiated G3 GEP-NET are also still "Lutathera orphans", and retreatment with RLT in patients with disease relapse is currently not approved. The aim of thiPharmaceutics1110https://www.ebi.ac.uk/biostudies/studies/S-EPMC10142322biostudies-literatureLutathera^® Orphans: State of the Art and Future Application of Radioligand Therapy with ¹⁷⁷Lu-DOTATATE.PMC10142322Bissoli SArtioli PCittanti CMarzola MCBartolomei MUrso LPorto FCastellani MUccelli LEvangelista LCastello ANieri AFlorimonte LBoschi AfalseLutathera^® Orphans: State of the Art and Future Application of Radioligand Therapy with ¹⁷⁷Lu-DOTATATE.Lutathera^® is the first EMA- and FDA-approved radiopharmaceutical for radioligand therapy (RLT). Currently, on the legacy of the NETTER1 trial, only adult patients with progressive unresectable somatostatin receptor (SSTR) positive gastroenteropancreatic (GEP) neuroendocrine neoplasms (NET) can be treated with Lutathera^®. Conversely, patients with SSTR-positive disease arising from outside the gastroenteric region do not currently have access to Lutathera^® treatment despite several papers in the literature reporting the effectiveness and safety of RLT in these settings. Moreover, patients with well-differentiated G3 GEP-NET are also still "Lutathera orphans", and retreatment with RLT in patients with disease relapse is currently not approved. The aim of thi2023-01-01T00:00:00Z2023 Mar2025-04-04T21:14:32.779Z2024-11-06T12:05:33.601ZS-EPMC101423223711159610.3390/pharmaceutics15041110